Literature DB >> 8168995

Cyclin D1 protein expression and function in human breast cancer.

J Bartkova1, J Lukas, H Müller, D Lützhøft, M Strauss, J Bartek.   

Abstract

Cyclin D1 is a cell-cycle regulator essential for G1 phase progression and a candidate proto-oncogene implicated in pathogenesis of several human tumour types, including breast carcinomas. In spite of the accumulating genetic evidence, however, there are no data regarding abundance and properties of the cyclin D1 protein in breast cancer. We now report aberrant nuclear overexpression/accumulation of the cyclin D1 protein in about half of the 170 primary breast carcinoma specimens analyzed by monoclonal antibody immunohistochemistry, indicating that the frequency of cyclin D1 abnormalities may be considerably higher than previously deduced from DNA amplification studies. A comparison of the expression patterns in matched lesions at different stages of tumour progression revealed that the cyclin D1 protein aberration appears to reflect a relatively early event and that, when acquired by a tumour, it is maintained throughout breast cancer progression including metastatic spread. In both tumour tissues and breast cancer cell lines, the abundance of this protein shows characteristic variations consistent with a cell-cycle oscillation and the peak levels expressed in G1. In all 7 cell lines whose retinoblastoma (Rb) protein is mutant or complexed to SV40 T antigen, exceptionally low levels of cyclin D1 protein and mRNA were found. Antibody-mediated and anti-sense oligonucleotide knockout experiments demonstrate the requirement for the cell-cycle regulatory function of cyclin D1 in breast cancer lines with single or multiple copies of the gene and reveal the absence of such a requirement in the cell lines with Rb defects. Our data are consistent with the notion that the emerging "Rb-cyclin D1 pathway" represents a frequent target of oncogenic abnormalities in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8168995     DOI: 10.1002/ijc.2910570311

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  138 in total

1.  Lactation defect in mice lacking the helix-loop-helix inhibitor Id2.

Authors:  S Mori; S I Nishikawa; Y Yokota
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

Review 2.  A specific role for cyclin D1 in mammary gland development.

Authors:  P Sicinski; R A Weinberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

3.  Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.

Authors:  E Neuman; M H Ladha; N Lin; T M Upton; S J Miller; J DiRenzo; R G Pestell; P W Hinds; S F Dowdy; M Brown; M E Ewen
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Authors:  Vandana Gupta Abramson; Andrea B Troxel; Michael Feldman; Carolyn Mies; Yan Wang; Lauren Sherman; Sara McNally; Alan Diehl; Angela Demichele
Journal:  Anticancer Res       Date:  2010-04       Impact factor: 2.480

5.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

6.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

7.  Cyclin D1 overexpression perturbs DNA replication and induces replication-associated DNA double-strand breaks in acquired radioresistant cells.

Authors:  Tsutomu Shimura; Yasushi Ochiai; Naoto Noma; Toshiyuki Oikawa; Yui Sano; Manabu Fukumoto
Journal:  Cell Cycle       Date:  2013-02-06       Impact factor: 4.534

8.  Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2.

Authors:  Lisa K Pierson-Mullany; Carol A Lange
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

9.  A better cell cycle target for gene therapy of colorectal cancer: cyclin G.

Authors:  Rodrigo Perez; Nancy Wu; Adam A Klipfel; Robert W Beart
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

Review 10.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.